Sakar Healthcare Q2FY27 Results: Revenue Up 52% to ₹8,741 Lakhs, PAT Soars 149% to ₹1,131 Lakhs
Sakar Healthcare's Q2 FY27 results show a 52% revenue increase to ₹8,741 lakhs and a 149% PAT surge to ₹1,131 lakhs. H1 FY27 revenue grew 45% to ₹16,038 lakhs, with PAT up 134% to ₹2,159 lakhs. The company also reported progress in its oncology business with new contracts and regulatory approvals.
The significant double-digit growth in key financial metrics like revenue and profit, coupled with positive operational updates in the high-potential oncology segment, is expected to have a considerable positive impact on investor confidence and the company's market valuation.
The company reported substantial year-on-year growth in revenue, EBITDA, and PAT for both the quarter and half-year, indicating strong financial performance and operational efficiency.
Sakar Healthcare Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026.
For the second quarter of FY27, the company reported a consolidated revenue from operations of ₹8,741.61 lakhs, a significant increase of 52% compared to ₹5,756.04 lakhs in Q2 FY26. EBITDA surged by 114% to ₹2,434.53 lakhs from ₹1,135.39 lakhs in the same period last year. Profit After Tax (PAT) saw a remarkable jump of 149%, reaching ₹1,130.69 lakhs in Q2 FY27, compared to ₹453.98 lakhs in Q2 FY26. Basic EPS for the quarter stood at ₹5.08.
In the first half of FY27, consolidated revenue grew by 45% to ₹16,038.86 lakhs from ₹11,029.66 lakhs in H1 FY26. EBITDA increased by 90% to ₹4,559.42 lakhs, and PAT more than doubled, rising by 134% to ₹2,159.18 lakhs from ₹921.11 lakhs in H1 FY26. Basic EPS for H1 FY27 was ₹9.70.
The company highlighted operational achievements including 69 oncology product contracts executed, 33 tech transfer projects underway, and 6 more product site variations approved by EMA. Sakar Healthcare is strengthening its global oncology presence and moving towards an integrated, regulatory-driven business model.
What to do with a filing like this
Sakar Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sakar Healthcare Limited. Read the original for the full detail.